Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2
- 1 March 1991
- journal article
- case report
- Published by Elsevier in Surgical Neurology
- Vol. 35 (3) , 244-247
- https://doi.org/10.1016/0090-3019(91)90079-o
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrierJournal of Neurosurgery, 1988
- Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2Journal of Neurosurgery, 1987
- The HTLV-III envelope protein contains a hexapeptide homologous to a region of interleukin-2 that binds to the interleukin-2 receptorBiochemical and Biophysical Research Communications, 1986
- Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinomaNeurology, 1983
- Treatment for meningeal carcinomatosis in breast cancerCancer, 1982
- Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patientsCancer, 1982
- Meningeal CarcinomatosisArchives of Neurology, 1981
- The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.The Journal of Immunology, 1980